U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807463) titled 'A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease' on Jan. 29.
Brief Summary: The primary efficacy objective of the trial is to assess the ability of TEV-53408 to attenuate gluten-induced enteropathy in adults with celiac disease.
The primary safety objective of the trial is to assess the safety of TEV-53408 in adults with celiac disease.
A secondary objective is to further assess the efficacy of TEV-53408 in adults with celiac disease.
The expected trial duration per participant is approximately 86 weeks.
Study Start Date: Feb. 17
Study Type: INTERVENTIONAL
Condition:
Celiac Disease
Interve...